Henry Meds GLP-1vsMochi Health Compounded GLP-1

Henry Meds prescribes compounded versions of GLP-1 receptor agonists, primarily semaglutide (the molecule in Ozempic and Wegovy) and tirzepatide (in Mounjaro and Zepbound). These drugs mimic the gut hormone GLP-1 (tirzepatide also mimics GIP), which slows stomach emptying, signals fullness to the brain, and improves how the body regulates blood sugar and appetite. The result is reduced hunger, smaller portions, and weight loss. "Compounded" means a licensed pharmacy mixes the medication rather than it being a mass-produced, FDA-approved finished product; the FDA has warned that some compounders have used unapproved salt forms (such as semaglutide sodium or acetate) that differ from the base molecule in the approved drugs.

You take a weekly subcutaneous injection of compounded semaglutide (a GLP-1 receptor agonist) or compounded tirzepatide (a dual GIP/GLP-1 agonist). These hormones slow how fast your stomach empties and signal fullness to the brain, so you eat less without feeling deprived. A Mochi clinician sets your starting dose and titrates it upward over weeks to balance results against side effects.

Henry Meds has not published its own clinical trials; efficacy is inferred from studies of the same active molecules. In the pivotal STEP 1 trial (NEJM 2021, 1,961 adults over 68 weeks), once-weekly 2.4 mg semaglutide produced a mean 14.9% reduction in body weight versus 2.4% with placebo, and 86.4% of participants lost at least 5% of their body weight. Tirzepatide produced even larger average losses in its SURMOUNT program. Important caveat: compounded products are not FDA-approved and are not tested for the same bioequivalence, and Henry Meds' lower-strength and oral/sublingual formulations lack the trial evidence that supports the brand injectables, so individual results may differ and could be lower than the trial figures.

Mochi uses the same active molecules studied in landmark trials. In STEP 1, branded semaglutide 2.4 mg produced about 14.9% average body-weight loss over 68 weeks; in SURMOUNT-1, branded tirzepatide 15 mg produced about 20.9% over 72 weeks. Compounded formulations are not separately FDA-tested, so trial results for branded drugs are a reference point, not a guarantee. Individual results vary.

The most common side effects are gastrointestinal: nausea, vomiting, diarrhea, and constipation, which are usually mild-to-moderate and worst during dose escalation. In STEP 1, about 4.5% of semaglutide users discontinued because of GI effects versus 0.8% on placebo. Serious but rarer risks include acute pancreatitis (severe abdominal pain), gallbladder disease, kidney injury from dehydration, and low blood sugar (especially when combined with other diabetes medications). All GLP-1 drugs in this class carry a boxed warning for thyroid C-cell tumors seen in rodents. The FDA has separately flagged compounded products for dosing errors and quality issues, including multiple adverse-event reports, some requiring hospitalization, tied to incorrect self-measured doses.

Most side effects are gastrointestinal (nausea, diarrhea, constipation, vomiting) and tend to ease as your body adjusts and as the dose is titrated slowly. Rare but serious risks include pancreatitis and gallbladder disease. Because the product is compounded, dosing-error and quality risks exist; report unusual symptoms to your clinician promptly. This is educational information, not medical advice.

As of September 2026, Henry Meds says its GLP-1 treatment starts at $179/month and that the price includes provider visits, medication, supplies and ongoing support, with the exact amount varying by treatment plan and dose. There is no separate membership fee. Compounded GLP-1s are essentially never covered by insurance, so plan to pay out of pocket. Note BBB complaints about auto-renewal billing, unexpected price increases and refunds: cancel before renewal and confirm the current price at signup.

As of September 2026, Mochi's membership is $39 for the first month and $79/month after that, and compounded semaglutide starts at $60/month on top of the membership — about $139/month combined at the lowest price point, before dose increases. Tirzepatide costs more. Insurance does not cover compounded medication. Check the current medication price for your dose at checkout.

Generally aimed at adults seeking weight management who meet clinical criteria assessed during the telehealth intake, typically a BMI of 30 or higher, or 27 or higher with a weight-related condition such as high blood pressure, prediabetes, or high cholesterol. You must NOT use these drugs if you or a family member has a history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). They are contraindicated in pregnancy and breastfeeding, generally avoided with a history of pancreatitis, and require caution with gallbladder disease, diabetic retinopathy, or severe gastrointestinal disease. Your prescriber makes the final eligibility call. Anyone whose insurance covers FDA-approved Wegovy or Zepbound should weigh those first.

Generally for US adults seeking medical weight management who clear a clinician's telehealth evaluation. Not appropriate for people with a personal or family history of medullary thyroid carcinoma or MEN 2, and not for use during pregnancy. State availability varies.